All In Biotech

Drug Trial Radar · NCT05537090

A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants

A Single Center, Open-label, 3-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxymidazolam in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Sep 1, 2022

Primary completion

Jul 31, 2023

Study completion Sep 30, 2023

Sponsor

Lead sponsor
BioVersys AGIndustry
Sponsor type
Industry
Collaborators
Clinical Research Units Hungary
First posted
Sep 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the effect of repeated doses of intravenous BV100 on the pharma-cokinetics of midazolam and 1-hydroxymidazolam.

Conditions

  • Healthy Volunteers

Interventions

  • BV100Drug

    Rifabutin for Infusion

  • MidazolamDrug

    Syrup for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of midazolamTime frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7
  2. To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of midazolamTime frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7
  3. To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of 1-hydroxymidazolamTime frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7
  4. To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of 1-hydroxymidazolamTime frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRU Hungary Kft., Early Phase Unit

    Kistarcsa, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.